Steve Prestrelski, PhD, is the Founder and Chief Scientific Officer of Xeris Pharmaceuticals. He has been working in the area of biopharmaceutical development and innovative drug delivery. Prior to starting Xeris, Dr Prestrelski held technical and management positions at Amgen, Alza (since acquired by J&J), PowderJect Technologies (since acquired by Chiron, itself acquired by Novartis), AlgoRx Technologies and Amylin (since acquired by Bristol-Myers Squibb and AstraZeneca). He is responsible for the development of several approved drug products globally. He has more than 50 peer-reviewed publications and is an inventor on >100 patents worldwide.